Apyx Medical Corporation (NASDAQ:APYX) is expected to report third quarter earnings results, before market open, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.16 per share.
Looking ahead, the full year loss are expected at $ 0.51 per share on the revenues of $ 22.18 million.
Previous Quarter Performance
Apyx Medical Corporation outlined loss for the second quarter of $ 0.14 per share, from the revenue of $ 4.30 million. The quarterly revenues shrunk 34.55 percent compared with the same quarter last year. According to street consensus, APYX was expected to report 2Q20 loss of $ 0.21 per share from revenue of $ 1.96 million. The bottom line results beat street analysts by $ 0.07 or 33.33 percent, at the same time, top line results outshined analysts by $ 2.34 million or 119.39 percent.
Stock Performance
On Friday, shares of Apyx Medical Corporation has traded high as $ 6.24 and has cracked $ 5.98 on the downward trend, reaching $ 5.98 with volume of 37.20 thousand shares.
According to the previous trading day, closing price of $ 5.98, representing a 119.22 % increase from the 52 week low of $ 2.81 and a 28.29 % decrease over the 52 week high of $ 8.59.
The company has a market capital of $ 204.61 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Apyx Medical Corporation will be hosting a conference call at 8:00 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website apyxmedical.com
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.
